Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
FPIs turn bullish on India as short covering drives market higher
27/10/2025
iPhone boom powers India’s electronics exports to record highs, set to overtake petroleum
27/10/2025
Will Nifty’s rally stall near 26,000 or break past its record high soon ?
27/10/2025
SMBC to share its global learning with Yes Bank, help raise the bar : CEO
26/10/2025
Skill financing scheme, Pradhan Mantri Kaushal Mudra Yojana, likely to be unveiled in Budget
26/10/2025
Did Radhakishan Damani dump Trent ? Inside the retail king’s mysterious exit from Tata’s hottest stock
26/10/2025
